Quick Facts
| Property | Value |
|---|---|
| Category | Regenerative / Tissue Repair Peptide |
| Risk Level | Moderate/High |
| Administration | Subcutaneous Injection |
| Typical Frequency | 1–3 Times Weekly |
| Estimated Half-Life | Approximately 2–3 Days |
| Primary Research Interest | Tissue Repair / Recovery / Injury Support |
This material is provided strictly for educational and informational purposes related to peptide research and regenerative compounds. TB-500 is a biologically active experimental peptide with limited long-term human safety data. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL
At this concentration:
• 2 mg = 0.400 mL (40.0 units)
• 5 mg = 1.000 mL (100.0 units)
2. Route of Administration
TB-500 is most commonly administered as a subcutaneous injectable regenerative peptide compound.
- Primary Route: SubQ Injection
- Preferred Timing: Flexible timing depending on injury recovery protocol
- Administration Notes: Loading phases followed by lower-frequency maintenance phases are commonly discussed
3. Typical Research Protocols
- Product Strength: 5.00 mg/mL
- Typical Delivered Amount: Loading phase of 2–5 mg three times weekly for 4 weeks, followed by maintenance dosing of 2–5 mg once weekly
- Frequency: Loading phase: 3× weekly / Maintenance phase: 1× weekly
- Cycle Length: 6–8 weeks on / 8 weeks off, PRN (as needed) for injury recovery
- Special Notes: Due to theoretical links involving tissue growth and angiogenesis signaling, use of TB-500 and similar regenerative peptides is often discouraged in individuals with a history of cancer or malignancy. Concerns surrounding possible tumor growth promotion remain theoretical and are not definitively proven.
4. Summary
TB-500 is a synthetic peptide fragment derived from thymosin beta-4, a naturally occurring protein involved in cellular migration and tissue repair signaling.
Research and anecdotal interest in TB-500 primarily center around soft tissue recovery, injury rehabilitation, inflammation modulation, and connective tissue repair.
5. Mechanism of Action
TB-500 is believed to influence actin regulation, cellular migration, angiogenesis signaling, and tissue remodeling pathways.
- Enhanced cellular migration
- Improved tissue remodeling signaling
- Potential angiogenesis support
- Reduced inflammatory signaling
- Improved recovery from soft tissue injury
6. Potential Benefits
- Potential tendon and ligament recovery support
- Enhanced soft tissue repair signaling
- Reduced inflammation
- Improved recovery from musculoskeletal injury
- Potential mobility and flexibility improvements
7. Potential Risks / Side Effects
Moderate/High
- Injection site irritation
- Fatigue
- Headaches
- Nausea
- Theoretical angiogenesis-related tumor growth concerns
- Limited long-term human safety data
- Unknown long-term regenerative signaling effects
8. Half-Life
TB-500 is commonly discussed as having an estimated half-life of approximately 2–3 days.
This longer duration compared to some regenerative peptides contributes to its popularity in lower-frequency dosing protocols.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer or cancer history
- Pregnancy or breastfeeding
- Use alongside experimental angiogenic compounds
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Experimental regenerative medicine literature
- Peer-reviewed tissue repair journals
CKF Tide Tables 